敷爾佳(301371.SZ):重組Ⅲ型人源化膠原蛋白凍幹纖維現在已經註冊檢驗完成,預期臨牀階段要一年左右
格隆匯9月9日丨敷爾佳(301371.SZ)於2024年9月9日接受特定對象調研,就“目前公司Ⅲ類醫療器械進展怎麼樣了?”,公司表示,目前我們Ⅲ類醫療器械進展基本符合預期,進展較快的是我們的重組Ⅲ型人源化膠原蛋白凍幹纖維,現在已經註冊檢驗完成,接下來就是臨牀階段,預期臨牀階段要一年左右,如果進展能夠按照預期來,該品將是我們第一款面世的Ⅲ類醫療器械產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.